Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate |
2019-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47b4fef480d7f744dc957c57f811eca8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd3939027187abf61bf2f7a879f6053f |
publicationDate |
2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019275125-A1 |
titleOfInvention |
Abeta variants, assay, method and treatment of alzheimer's disease |
abstract |
The present invention relates to a new abeta immunogen variants that enables efficient treatment of Alzheimer's Disease patients by raising specific antibodies against oligimeric and toxic abeta deposits in the brain of Alzheimer's patients. The invention also relates to an assay that enables efficient treatment of Alzheimer's Disease patients by assessing and monitoring the titre response to active immune therapy, as well as treatment and identification of specific subpopulations of Alzheimer Disease patients |
priorityDate |
2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |